Skip Navigation
Skip to contents



10 results

Hypersensitivity Reactions to Oxaliplatin

Lee KH, Park YJ, Kim ES, Hwang HJ, Shim BY, Kim HK

  • Cancer Res Treat.
  • 2006 Dec;38(4):240-241.
Oxaliplatin is a third-generation platinum compound that is used as a single agent and in combination with fluorouracil (5-FU) to treat colorectal and gastric carcinoma. The patients treated with oxaliplatin...
Mouse Orthotopic Lung Cancer Model Induced by PC14PE6

Cui ZY, Ahn JS, Lee JY, Kim WS, Lim HY, Jeon HJ, Suh SW, Kim JH, Kong WH, Kang JM, Nam DH, Park K

  • Cancer Res Treat.
  • 2006 Dec;38(4):234-239.
PURPOSE: This study was undertaken to investigate in detail the xenograft mouse orthotopic lung cancer model induced by PC14PE6 adenocarcinoma cells. MATERIALS AND METHODS: Three cell doses (0.5x10(6); 1x10(6); 2x10(6)) of...
The Effect of Pentoxifylline on Radiobiological Parameters in the Rat Radiation Myelopathy

Kim WD, Park WY

  • Cancer Res Treat.
  • 2006 Dec;38(4):229-233.
PURPOSE: There is great recent interest in the potential value of using pentoxifylline (3,7-dimethyl-1(5-oxyhexyl)- xanthine, PTX) as an inhibitor of radiation-induced late normal tissue damage. The effects of PTX on...
p53 Prevents Immature Escaping from Cell Cycle G2 Checkpoint Arrest through Inhibiting cdk2-dependent NF-Y Phosphorylation

Yun UJ, Park HD, Shin DY

  • Cancer Res Treat.
  • 2006 Dec;38(4):224-228.
PURPOSE: Recent studies have suggested that p53 regulates the G2 checkpoint in the cell cycle and this function is required for the maintenance of genomic integrity. In this study, we...
Prognostic Significance of Immunohistochemical Expression of p53 Gene Product in Operable Breast Cancer

Song HS, Do YR, Kang SH, Jeong KY, Kim YS

  • Cancer Res Treat.
  • 2006 Dec;38(4):218-223.
PURPOSE: The aim of this study was to investigate the prognostic significance of the expression of p53 gene product in operable invasive breast cancer by performing immunohistochemical analysis. MATERIALS AND...
An Evaluation of Nutrition Support for Terminal Cancer Patients at Teaching Hospitals in Korea

Kim DY, Lee SM, Lee KE, Lee HR, Kim JH, Lee KW, Lee JS, Lee SN

  • Cancer Res Treat.
  • 2006 Dec;38(4):214-217.
PURPOSE: We wanted to analyze the use of nutrition support for terminal cancer patients, the effect of discussing withdrawal of nutrition support and do-not- resuscitate (DNR) consent on the use...
Gemcitabine Single or Combination Chemotherapy in Post Anthracycline and Taxane Salvage Treatment of Metastatic Breast Cancer: Retrospective Analysis of 124 Patients

Kim MK, Kim SB, Ahn JH, Lee SI, Ahn SH, Son BH, Gong G, Kim HH, Lee JS, Kang YK, Kim WK

  • Cancer Res Treat.
  • 2006 Dec;38(4):206-213.
PURPOSE: To evaluate the efficacy of gemcitabine- based chemotherapy, particularly in patients with anthracycline- and taxane-pretreated 2(nd)-line or greater metastatic breast cancer, and to compare gemcitabine monotherapy (G) with two...
Phase II Study of Oxaliplatin, 5-fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as Second Line Therapy

Lee DJ, Oh HS, Choi JH, Lee YY, Kim IS, Ahn MJ

  • Cancer Res Treat.
  • 2006 Dec;38(4):201-205.
PURPOSE: The purpose of the study was to assess the efficacy and safety of biweekly oxaliplatin in combination with leucovorin (LV)-modulated bolus plus infusion of 5-fluorouracil (5-FU) in patients with...
Lapatinib : Overview and Current Role in Metastatic Breast Cancer

Chan A

  • Cancer Res Treat.
  • 2006 Dec;38(4):198-200.
No Author listed.
Tumor Angiogenesis: Initiation and Targeting : Therapeutic Targeting of an FGF-Binding Protein, an Angiogenic Switch Molecule, and Indicator of Early Stages of Gastrointestinal Adenocarcinomas

Tassi E, Wellstein

  • Cancer Res Treat.
  • 2006 Dec;38(4):189-197.
Tumor angiogenesis has been related to the initiation as well as progression toward more aggressive behavior of human tumors. In particular, the activity of angiogenic factors is crucial for tumor...

Go to Top

Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: